- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01746030
Geriatric Assessments in Senior Adults With Multiple Myeloma
Pilot Study of Geriatric Assessments in Senior Adults With Multiple Myeloma
This study will evaluate the prevalence of geriatric syndromes in older adults with multiple myeloma, examine relationships between baseline geriatrics syndromes and initial treatment selection, and examine risk of functional decline.
Relationship between baseline geriatric questionnaires and initial treatment selection in older adults with newly diagnosed multiple myeloma.
Feasibility of subjects completing the CARG geriatric assessments at baseline, 3 months and 6 months.
Comorbidities or dependence in IADLs at baseline predict decline in functional status at 6 months of follow-up in older adults with newly diagnosed multiple myeloma.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
Missouri
-
St. Louis, Missouri, Forenede Stater, 63110
- Washington University School of Medicine
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Patient must have a diagnosis of multiple myeloma by IMWF criteria: diagnosis must have occurred within 3 months of study enrollment.
- Patient must be ≥ 65 years of age.
- Patient's life expectancy must be ≥ 6 months.
- Patient must be willing to complete follow-up assessments.
- Patient must be able to understand and willing to sign a written informed consent document.
Exclusion Criteria:
- Patient must not have a diagnosis of smoldering myeloma.
- Patient must not have concomitant amyloidosis.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
---|
Questionnaires
No treatment
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
The relationship between initial treatment recommendation and baseline questionnaires assessment
Tidsramme: At baseline visit
|
The physician caring for the patient will be asked to identify his/her initial treatment recommendations.
This includes whether the patient is, in his/her assessment, a candidate for high dose therapy and autologous stem cell transplantation.
It will also include whether a 2-drug or 3-drug regimen is recommended initially.
|
At baseline visit
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Changes in questionnaires from baseline to 6 months
Tidsramme: Through 6 months of follow-up
|
Logistic regression analyses, adjusted odds ratios (ORs) based on model will be given with 95% CIs.
All analyses will use two-tailed significance levels of 0.05 and will be conducted with statistical software SAS 9.2.
Geriatric assessment variables will be analyzed as continuous or ordinal variables as indicated.
Candidate variables will include: demographic data (including age, gender, race), disease data (stage, cytogenetic abnormalities), or geriatric assessment variables (comorbidity, functional status, physical function, psychological state, nutrition, social support and social activity).
Analyses will be performed for the outcomes of treatment selection (transplant vs non-transplant) and increased dependence in IADLs
|
Through 6 months of follow-up
|
Completion of the questionnaires at baseline, 3 months and 6 months.
Tidsramme: Baseline, 3 months, and 6 months
|
Feasibility of subjects completing questionnaires is defined as 90% of consenting subjects completing the baseline geriatric assessment battery, and 80% of consenting subjects completing follow-up assessments at 3 and 6 months.
|
Baseline, 3 months, and 6 months
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Tanya Wildes, M.D., Washington University School of Medicine
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hjerte-kar-sygdomme
- Karsygdomme
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Hæmatologiske sygdomme
- Hæmoragiske lidelser
- Hæmostatiske lidelser
- Paraproteinæmier
- Blodproteinforstyrrelser
- Myelomatose
- Neoplasmer, Plasmacelle
Andre undersøgelses-id-numre
- 201207060
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .